The association between psoriasis and streptococcal infection has been widely explored in both children and adults. However, the exact impact of Streptococcus pharyngeal infection on the course of psoriasis is not fully comprehended. This study explored the impact of Streptococcus pharyngeal infection on psoriasis and investigated the effectiveness of systemic antibiotic therapy in conjunction with standard topical treatment for psoriatic patients with concomitant streptococcal throat infection. The research involved 115 patients with mild-to-moderate psoriasis, clinically assessed using the Psoriasis Area and Severity Index (PASI). Patients with active streptococcal infection were administered adjunctive systemic antibiotic therapy along with standard local treatment for psoriasis, while psoriasis patients without evidence of infection received the local topical treatment only. Streptococcal infections were more common in psoriasis patients compared to healthy controls. A group of psoriasis patients with active streptococcal throat infections, treated with antibiotics in addition to standard topical psoriasis therapy, did not show any difference in PASI score reduction compared to those without evidence of active infection. While our study did not show a statistically significant reduction in PASI scores in psoriasis patients with streptococcal throat infections treated with antibiotics, it highlights the complex interaction between infection and psoriasis. Larger studies with longer follow-up may better clarify this relationship, contributing to stronger evidence for or against the use of antibiotics in managing psoriasis triggered by streptococcal infections.

Journal of the European Academy of Dermatology and VenereologyEarly View LETTER TO THE EDITOR Reply to 'New onset of systemic lupus erythematosus following COVID-19 mRNA vaccination' This article relates to: New onset of systemic lupus erythematosus following COVID-19 mRNA vaccination E. Hansen, R. Feldmann, R. Pirker, J. Jochmann, F. Breier, C. Posch, Volume 38Issue 1Journal of the European Academy of Dermatology and Venereology pages: e6-e7 First Published online: September 19, 2023 E. Magnaterra, E. Magnaterra orcid.org/0000-0002-3263-4353 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorE. B. Mariotti, Corresponding Author E. B. Mariotti [email protected] orcid.org/0000-0003-0388-1037 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy Correspondence E. B. Mariotti, Viale Michelangiolo 41, Firenze 50125, Italy. Email: [email protected]Search for more papers by this authorA. Corrà, A. Corrà Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorC. Aimo, C. Aimo orcid.org/0000-0002-9394-2077 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorL. Quintarelli, L. Quintarelli orcid.org/0000-0002-9228-8042 Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this authorV. Ruffo di Calabria, V. Ruffo di Calabria orcid.org/0000-0003-0307-6636 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorA. Verdelli, A. Verdelli Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this authorM. Caproni, M. Caproni orcid.org/0000-0002-7471-3471 Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this author E. Magnaterra, E. Magnaterra orcid.org/0000-0002-3263-4353 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorE. B. Mariotti, Corresponding Author E. B. Mariotti [email protected] orcid.org/0000-0003-0388-1037 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy Correspondence E. B. Mariotti, Viale Michelangiolo 41, Firenze 50125, Italy. Email: [email protected]Search for more papers by this authorA. Corrà, A. Corrà Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorC. Aimo, C. Aimo orcid.org/0000-0002-9394-2077 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorL. Quintarelli, L. Quintarelli orcid.org/0000-0002-9228-8042 Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this authorV. Ruffo di Calabria, V. Ruffo di Calabria orcid.org/0000-0003-0307-6636 Section of Dermatology, Department of Health Sciences, University of Florence, Florence, ItalySearch for more papers by this authorA. Verdelli, A. Verdelli Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this authorM. Caproni, M. Caproni orcid.org/0000-0002-7471-3471 Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, ItalySearch for more papers by this author First published: 08 December 2023 https://doi.org/10.1111/jdv.19693Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Open Research DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analysed in this study. REFERENCES 1Hansen E, Feldmann R, Pirker R, Jochmann J, Breier F, Posch C. New onset of systemic lupus erythematosus following COVID-19 mRNA vaccination. J Eur Acad Dermatol Venereol. 2023; https://doi.org/10.1111/jdv.19513 Epub ahead of print. 10.1111/jdv.19513 Google Scholar 2Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349(16): 1526–1533. https://doi.org/10.1056/NEJMoa021933 10.1056/NEJMoa021933 CASPubMedWeb of Science®Google Scholar 3Joseph AK, Chong BF. Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine. Dermatol Ther. 2021; 34(6):e15114. https://doi.org/10.1111/dth.15114 10.1111/dth.15114 CASPubMedWeb of Science®Google Scholar 4Niebel D, Ralser-Isselstein V, Jaschke K, Braegelmann C, Bieber T, Wenzel J. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021; 34(4):e15017. https://doi.org/10.1111/dth.15017 10.1111/dth.15017 PubMedWeb of Science®Google Scholar 5Magnaterra E, Magliulo M, Mariotti EB, Ruffo DI, Calabria V, Quintarelli L, et al. Subacute cutaneous lupus erythematosus induced by Pfizer COVID-19 vaccine. Ital J Dermatol Venerol. 2023; 158(3): 266–267. Chen Y, Xu Z, Wang P et al.; New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2021. PubMedGoogle Scholar 6Sprent J, King C. COVID-19 vaccine side effects: the positives about feeling bad. Sci Immunol. 2021; 6(60):eabj9256. 10.1126/sciimmunol.abj9256 PubMedWeb of Science®Google Scholar 7Verdelli A, Antiga E, Bonciolini V, Bonciani D, Volpi W, Caproni M. Drug induction in connective tissue diseases. G Ital Dermatol Venereol. 2014; 149(5): 573–580. CASPubMedWeb of Science®Google Scholar 8Aimo C, Mariotti EB, Corrà A, Ruffo di Calabria V, Quintarelli L, Verdelli A, et al. A case of dermatomyositis induced by Sars-Cov 2 infection. Italian J Dermatol. in press. Google Scholar 9Wu CF, Chen WT, Chen YL, Liu FC. Therapeutic effects of treating COVID-19 vaccine-induced anti-TIF1-γ-positive dermatomyositis. Medicina (Kaunas). 2023; 59(9):1688. https://doi.org/10.3390/medicina59091688 10.3390/medicina59091688 PubMedGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

None of the authors have any conflict of interest to disclose. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.